Piramal Pharma Solutions Wins at Prestigious CPhI Pharma Awards

FRANKFURT, Germany, Oct. 25, 2017 /CNW/ - Piramal Pharma Solutions (PPS) is pleased to announce that it was recognized as the winner of the 'Regulatory Procedures and Compliance' award at the prestigious CPhI Pharma Awards (2017) held on October 24 at the Intercontinental Hotel - Frankfurt, Germany. PPS competed with several of its global peers in this category- a category that is fundamental to serve the needs of our end customers. The CPhI Pharma Awards are among the most coveted recognitions in the pharmaceutical industry and celebrates thinkers and creators that break new ground, recognizing companies that drive the industry forward. With over 200 entries submitted in 19 different award categories, the CPhI Pharma Awards serve as a great barometer for industry excellence.

(Logo: http://photos.prnewswire.com/prnh/20170320/480020LOGO )

(Photo: http://mma.prnewswire.com/media/590387/Vivek_Sharma_Piramal_CPhI_Awards.jpg )

Upon receiving the award, Vivek Sharma, Chief Executive Officer of Piramal Pharma Solutions said: "It is a pleasure to accept the award on behalf of all the dedicated employees at Piramal Pharma Solutions that made this recognition possible. The award serves as a testament to our efforts that advances Piramal Pharma Solutions from 'Quality for Compliance' to 'Quality as a Culture'. Our 'One Piramal' strategy is built around the values of Customer Centricity, Quality, and Innovation. It is great to be recognized by our fellow peers and customers on one of our core values."

"We recognize that as an industry, we serve a higher purpose: Delivering solutions for our customers that improve the standard of life and reduce the burden of disease in patients. In order to accomplish these successfully, a robust quality and regulatory compliance record is a must. We therefore take enormous pride in this recognition," he added.

PPS is a leading global Contract Development and Manufacturing Organization (CDMO), with 12 locations in North America, Europe, and Asia, driving solutions for our customers, from discovery through commercialization. With a stellar track record that includes 34 launched products for customers, Piramal is now a 'partner of choice' for leading pharmaceutical and biotech firms in North America and Europe.

PPS' global capabilities include, Discovery Chemistry Support, Drug Substance Development and Manufacturing, Formulation Development through Commercialization, and Clinical Trial Supplies. Further, Piramal is a leader in developing and manufacturing Antibody Drug Conjugates (ADCs) from early development to launch. With a commitment to investing capital that meet our customers' future needs, a robust balance sheet, a strong management team, and a focus on customer centricity, PPS expects to continue to make a positive impact in human life for years to come.

About Piramal Enterprises Limited:

Piramal Enterprises Limited (PEL) is one of India's large diversified companies, with a presence in financial services, pharmaceuticals and healthcare insights & analytics. PEL's consolidated revenues were over US$1.3 billion in FY2017, with 51% of revenues generated from outside India.

In Financial Services, PEL provides comprehensive financing solutions to real estate companies. The division's Corporate Finance Group (CFG) also provides senior and mezzanine growth capital to various businesses across varied sectors that are integral part of India's growth story. The Division has also launched Distressed Asset Investing platform that will invest in equity and/or debt in assets across sectors (other than real estate) to drive restructuring with active participation in turnaround. The total funds under management under all these businesses are over US$5.5 billion. The Company has recently launched a retail housing finance vertical. The Company also has strategic alliances with top global funds such as APG Asset Management, Bain Capital Credit, CPPIB Credit Investment Inc. and Ivanhoé Cambridge (CDPQ). PEL also has long term equity investments worth ~US$1 billion in Shriram Group, a leading financial conglomerate in India.

In Pharma, through an end-to-end manufacturing capabilities across 13 global facilities and a large global distribution network to over 100 countries, PEL sells a portfolio of niche differentiated pharma products and provides an entire pool of pharma services (including in the areas of injectable, HPAPI etc.). The Company is also strengthening its presence in the Consumer Product segment in India.

PEL's Healthcare Insights & Analytics business, Decision Resources Group, is the premier provider of healthcare analytics, data & insight products and services to the world's leading pharma, biotech and medical technology companies and enables them to take informed business decisions.

PEL is listed on the BSE Limited and the National Stock Exchange of India Limited in India.

SOURCE Piramal Pharma Solutions

For Investors: Hitesh Dhaddha / Bhavna Sinyal, Investor Relations, Contact: [phone] / 6570, Email: [email protected]; For Media Queries: Dimple Kapur / Rohan Sharma, Corporate Communications, Contact: [phone] / 4094, Email: [email protected] / [email protected]